News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,456 Results
Type
Article (13898)
Company Profile (295)
Press Release (246263)
Section
Business (79350)
Career Advice (150)
Deals (13188)
Drug Delivery (32)
Drug Development (50301)
Employer Resources (31)
FDA (5673)
Job Trends (5115)
News (144121)
Policy (10023)
Tag
Academia (903)
Alliances (21478)
Alzheimer's disease (736)
Approvals (5648)
Artificial intelligence (63)
Bankruptcy (97)
Best Places to Work (4498)
Biotechnology (242)
Breast cancer (66)
Cancer (699)
Cardiovascular disease (62)
Career advice (131)
CAR-T (57)
Cell therapy (178)
Clinical research (39829)
Collaboration (239)
Compensation (99)
COVID-19 (1003)
C-suite (68)
Cystic fibrosis (66)
Data (798)
Diabetes (73)
Diagnostics (1201)
Earnings (28986)
Events (46877)
Executive appointments (193)
FDA (5967)
Funding (252)
Gene editing (55)
Gene therapy (148)
GLP-1 (301)
Government (1063)
Healthcare (6536)
Infectious disease (1038)
Inflammatory bowel disease (94)
IPO (7184)
Job creations (861)
Job search strategy (126)
Layoffs (184)
Legal (1376)
Lung cancer (111)
Manufacturing (74)
Medical device (2552)
Medtech (2553)
Mergers & acquisitions (6108)
Metabolic disorders (225)
Neuroscience (946)
NextGen Class of 2024 (1998)
Non-profit (844)
Northern California (954)
Obesity (124)
Opinion (91)
Parkinson's disease (61)
Patents (52)
People (24992)
Pharmaceutical (50)
Phase I (14013)
Phase II (18526)
Phase III (11741)
Pipeline (324)
Postmarket research (847)
Preclinical (5930)
Radiopharmaceuticals (206)
Rare diseases (169)
Real estate (1410)
Regulatory (8212)
Research institute (931)
Southern California (868)
Startups (1964)
United States (7657)
Vaccines (161)
Weight loss (76)
Date
Today (1)
Last 7 days (419)
Last 30 days (2158)
Last 365 days (20740)
2024 (19070)
2023 (22414)
2022 (26825)
2021 (27819)
2020 (23369)
2019 (16236)
2018 (11746)
2017 (13755)
2016 (11854)
2015 (14353)
2014 (10396)
2013 (7490)
2012 (7550)
2011 (7616)
2010 (7430)
Location
Africa (146)
Asia (16833)
Australia (2840)
California (2161)
Canada (718)
China (166)
Colorado (82)
Connecticut (86)
Europe (36272)
Florida (232)
Georgia (62)
Illinois (126)
Indiana (54)
Kansas (55)
Maryland (300)
Massachusetts (1712)
Michigan (48)
Minnesota (94)
New Jersey (549)
New York (615)
North Carolina (399)
Northern California (954)
Ohio (79)
Pennsylvania (429)
South America (207)
Southern California (868)
Texas (232)
Washington State (221)
260,456 Results for "kyn therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
Kynexis announced today that the first healthy volunteers have been dosed in its first-in-human phase 1 study of KYN-5356. KYN-5356, a clinical-stage small molecule targeting a key enzyme in the kynurenine pathway known as KAT-II, is being developed for cognitive impairment associated with schizophrenia (CIAS).
January 4, 2024
·
1 min read
Business
Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases
Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced the formation of its distinguished Scientific Advisory Board.
May 29, 2024
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Dr. Falk Pharma Acquires Kynos Therapeutics, Adding Acute Pancreatitis as a Therapeutic Focus and Further Strengthening Its Development Portfolio
October 29, 2024
·
4 min read
Kynexis Launched to Advance Precision Therapeutics for Brain Diseases
Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, launched with €57 million in Series A financing led by Forbion, with participation from Ysios Capital and Sunstone Life Science Ventures.
November 7, 2023
·
4 min read
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
Genetown
Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next Phase of Growth
Kyn Therapeutics, a clinical-stage biotechnology company, today announced it is rebranding to Ikena Oncology.
December 3, 2019
·
5 min read
Layoffs
Spero Therapeutics to Lay Off 39% of Employees
Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.
October 30, 2024
·
1 min read
·
Angela Gabriel
Layoffs
Viracta Therapeutics Cuts 42% of Staff as Part of Resource Reprioritization
Following two layoffs in less than three months, Viracta Therapeutics may have around 18 employees left to advance its efforts to bring lead product candidate nana-val to market.
November 7, 2024
·
2 min read
·
Angela Gabriel
Drug Development
Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement
Kynos Therapeutics Ltd announces the key findings from the first-in-human Phase I trial of its lead drug candidate, KNS366.
April 22, 2024
·
3 min read
1 of 26,046
Next
